GT Biopharma Reports Improved Financial Results with Reduced Losses in Q2 2025

GT Biopharma, Inc. has reported its financial results for the second quarter of 2025, revealing a net loss of $1.4 million for the three months ended June 30, 2025, a significant improvement compared to a net loss of $3.7 million during the same period in 2024. For the six months ended June 30, 2025, the company recorded a net loss of approximately $2.2 million, down from $6.0 million in the prior year. The reduction in losses is attributed to decreased operating expenses, particularly in research and development, which fell by 80% to $363,000 for the quarter, and by 43% to $1.5 million for the six-month period.

The company’s total assets increased to $7.1 million as of June 30, 2025, compared to $4.2 million at the end of 2024. This growth was primarily driven by an increase in cash and cash equivalents, which rose to $5.2 million from $4.0 million. Current liabilities also saw a significant decrease, dropping to $2.3 million from $5.9 million, resulting in a working capital improvement from a deficit of $1.7 million to a surplus of $4.8 million. The company’s stockholders’ equity shifted from a deficit of $1.7 million to a positive equity of $2.9 million, reflecting the successful completion of financing activities.

Strategically, GT Biopharma has made notable advancements in its product pipeline, particularly with its TriKE® technology. The company has initiated clinical trials for its next-generation product candidate, GTB-3650, which targets CD33 in patients with relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The FDA cleared the IND application for GTB-3650 in June 2024, and patient enrollment began in January 2025. Additionally, the company is preparing for the submission of an IND application for another candidate, GTB-5550, by the end of 2025.

In terms of operational metrics, GT Biopharma has focused on reducing costs and improving efficiency. The company reported a decrease in selling, general, and administrative expenses by 43% to $1.1 million for the second quarter, largely due to reduced legal fees and other cost-cutting measures. The company’s cash flow from financing activities was approximately $6.5 million for the first half of 2025, primarily from the issuance of Series L Convertible Preferred Stock and warrants, indicating a successful capital raise to support ongoing operations and development efforts.

Looking ahead, GT Biopharma faces challenges related to its ongoing financial viability, as it has not yet generated revenue from product sales and continues to incur operating losses. The company has expressed concerns about its ability to continue as a going concern if it cannot secure additional financing. Management has indicated that without further funding, it may need to delay or reduce its operational activities, which could adversely impact its business prospects. The company remains focused on advancing its clinical programs and securing the necessary capital to support its strategic objectives.